Evidence map›Paper›PMID 42363124›Full record

ArticleBMC cancer2026

Preparation, characterization and anticancer applications of HAase from Pedobacter heparinus.

Bo Dou, Ruiqi Wu, Xiaolai Ma, Changhua Hu, Xiaoqun Duan

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bo DouSchool of Pharmacy, Guilin Medical University, Guilin, 541199, Guangxi, China.
Ruiqi WuSchool of Pharmacy, Guilin Medical University, Guilin, 541199, Guangxi, China.
Xiaolai MaSchool of Pharmacy, Guilin Medical University, Guilin, 541199, Guangxi, China. 2246913382@qq.com.
Changhua HuSchool of Pharmaceutical Sciences, Medical Research Institute, Southwest University, Chongqing, 400715, China. 2573853815@qq.com.
Xiaoqun DuanSchool of Pharmacy, Guilin Medical University, Guilin, 541199, Guangxi, China. 17797511410@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyaluronidase (HAase) is an enzyme capable of degrading hyaluronic acid (HA). In anti-tumor therapy, HAase can enhance the efficacy of anti-cancer drugs by regulating the tumor microenvironment and overcoming drug delivery barriers, and it can also be used directly to inhibit tumor growth. In this study, we identified a previously uncharacterized HAase (Ph-HAase) from Pedobacter heparinus. After purification, the enzyme was obtained with a 43.08% recovery, a 47.5-fold purification, and a specific activity of 32.32 IU/mg. SDS-PAGE and LC-MS analyses revealed that the molecular weight of Ph-HAase was 79.6 kDa. Ph-HAase exhibited excellent stability at temperatures below 30 °C and within the pH range of 6.5 to 7.5. The enzyme activity was found to be relatively high at pH 6.5 and 45℃. Although HA served as the preferred substrate, Ph-HAase also exhibited degradative activity toward Chondroitin Sulfate (CS) and Dermatan Sulfate (DS). Notably, we found that Ph-HAase induced apoptosis in melanoma B16F10 cells via the mitochondrial pathway, characterized by loss of membrane potential and ROS accumulation, and affected the expression of apoptosis-related genes and proteins. In vivo studies further confirmed its anti-melanoma effect. This study is the first to report HAase derived from P. heparinus and to demonstrate its potential for melanoma treatment.

Indexed as

Antineoplastic AgentsHyaluronoglucosaminidasePedobacterAnimalsApoptosisCell Line, TumorChondroitin SulfatesDermatan SulfateHumansHyaluronic AcidHydrogen-Ion ConcentrationMelanoma, ExperimentalMiceAntineoplastic AgentsChondroitin SulfatesDermatan SulfateHyaluronic AcidHyaluronoglucosaminidaseAnticancerCharacterizationFermentationHyaluronidasePedobacter heparinus

Identifiers

PMID42363124
PMCPMC13563888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.